Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods
10.1016/s0197-2456(96)00106-7 · doi-reference
Obesity and preeclampsia: the potential role of inflammation
10.1016/s0029-7844(01)01551-4 · doi-reference
Maternal vitamin D intake during pregnancy and early childhood wheezing
10.1093/ajcn/85.3.853 · doi-reference
Study protocol. A prospective cohort study of unselected primiparous women: the pregnancy outcome prediction study
10.1186/1471-2393-8-51 · doi-reference
10.1086/431245
10.1086/431245 · doi-reference
Child health and the environment: the INMA Spanish Study
10.1111/j.1365-3016.2006.00745.x · doi-reference
Insulin-like growth factor I in pregnancy and maternal risk of breast cancer
10.1158/1055-9965.epi-06-0625 · doi-reference
The longitudinal study of the northern Finland birth cohort of 1966
10.1111/j.1365-3016.1988.tb00180.x · doi-reference
Nordic biological specimen banks as basis for studies of cancer causes and control—more than 2 million sample donors, 25 million person years and 100,000 prospective cancers
10.1080/02841860701203545 · doi-reference
The biobank of the Norwegian Mother and Child Cohort Study: a resource for the next 100 years
10.1007/s10654-006-9041-x · doi-reference
The Danish National Birth Cohort—its background, structure and aim
10.1177/14034948010290040201 · doi-reference
Patterns of change in uterine artery Doppler studies between 20 and 24 weeks of gestation and pregnancy outcomes
10.1097/aog.0b013e318195b223 · doi-reference
Association between maternal seafood consumption before pregnancy and fetal growth: evidence for an association in overweight women. The EDEN mother–child cohort
10.1111/j.1365-3016.2008.00982.x · doi-reference
Metabolic syndrome in early pregnancy and risk of preterm birth
10.1093/aje/kwp211 · doi-reference
Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia
10.1016/j.ajog.2004.12.052 · doi-reference
Low urinary placental growth factor is a marker of pre-eclampsia
10.1038/sj.ki.5000075 · doi-reference
Urinary placental growth factor and risk of preeclampsia
10.1001/jama.293.1.77 · doi-reference
First trimester urinary placental growth factor and development of pre-eclampsia
10.1111/j.1471-0528.2008.02074.x · doi-reference
Detection and identification of novel metabolomic biomarkers in preeclampsia
10.1177/1933719108316908 · doi-reference
A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia
10.1111/j.1471-0528.2009.02283.x · doi-reference
Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus
10.1161/hypertensionaha.109.130583 · doi-reference
Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice
10.1038/nm.1856 · doi-reference
AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia
10.1007/s00109-008-0332-4 · doi-reference
The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia
10.1002/uog.29 · doi-reference
The measurement of maternal plasma corticotropin-releasing factor (CRF) and CRF-binding protein improves the early prediction of preeclampsia
10.1210/jc.2004-0186 · doi-reference
Corticotrophin-releasing hormone and corticotrophin-releasing hormone binding protein in normal and pre-eclamptic human pregnancies
10.1111/j.1471-0528.1995.tb09063.x · doi-reference
Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants
10.1016/j.ajog.2007.05.052 · doi-reference
Plasma concentrations of asymmetric dimethylarginine (ADMA) in Colombian women with pre-eclampsia
10.1001/jama.291.7.823 · doi-reference
Reduced l-arginine level and decreased placental eNOS activity in preeclampsia
10.1016/j.placenta.2005.04.011 · doi-reference
Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia
10.1080/j.1600-0412.1998.770805.x · doi-reference
Asymmetric dimethylarginine (ADMA) in the maternal and fetal circulation in preeclampsia
10.1203/pdr.0b013e3181b33392 · doi-reference
Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia
10.1016/s0002-9378(98)70437-5 · doi-reference
Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia
10.1016/s0140-6736(03)13177-7 · doi-reference
The value of elevated second-trimester beta-human chorionic gonadotropin in predicting development of preeclampsia
10.1016/s0002-9378(97)70512-x · doi-reference
Mid-trimester beta-hCG levels incorporated in a multifactorial model for the prediction of severe pre-eclampsia
10.1002/1097-0223(200009)20:9<738::aid-pd917>3.0.co;2-r · doi-reference
Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry
10.1159/000081369 · doi-reference
Growth, development and health from early fetal life until young adulthood: the Generation R Study
10.1111/j.1365-3016.2003.00521.x · doi-reference
Maternal serum human chorionic gonadotropin level at 15 weeks is a predictor for preeclampsia
10.1016/s0002-9378(96)70247-8 · doi-reference
A microarray approach for systematic identification of placental-derived RNA markers in maternal plasma
10.1007/978-1-59745-066-9_22 · doi-reference
Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia
10.1016/j.ajog.2003.12.019 · doi-reference
